Share on StockTwits

A number of firms have modified their ratings and price targets on shares of AstraZeneca plc (ADR) (NYSE: AZN) recently:

  • AstraZeneca plc (ADR) was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating.
  • AstraZeneca plc (ADR) was upgraded by analysts at Credit Suisse from an “underperform” rating to a “neutral” rating.
  • AstraZeneca plc (ADR) had its “hold” rating reaffirmed by analysts at Deutsche Bank.
  • AstraZeneca plc (ADR) had its “hold” rating reaffirmed by analysts at Jefferies Group.
  • AstraZeneca plc (ADR) had its “equal weight” rating reaffirmed by analysts at Barclays.
  • AstraZeneca plc (ADR) was upgraded by analysts at Societe Generale from a “sell” rating to a “hold” rating. They now have a $100.00 price target on the stock.
  • AstraZeneca plc (ADR) had its “neutral” rating reaffirmed by analysts at Zacks. They now have a $72.00 price target on the stock. Zacks‘ analyst wrote, “AstraZeneca’s first-quarter 2014 core earnings of $1.17 per ADS missed the Zacks Consensus Estimate of $1.20. Earnings were also down 11% (at CER) year over year. AstraZeneca’s quarterly revenues increased 3% (at CER) year over year to $6.4 billion. Revenues were above the Zacks Consensus Estimate of $6.3 billion. AstraZeneca continues to expect 2014 revenues to decline in the low-to-mid single digits and core earnings to decline in the teens. We expect the top- and bottom-line to remain under pressure as Nexium goes off-patent in May 2014. We are nonetheless pleased with recent approvals (Forxiga and Myalept in the U.S. and Xigduo in the EU) at AstraZeneca. We are also positive on AstraZeneca’s efforts to advance its pipeline. We maintain a Neutral recommendation on the stock.”
  • AstraZeneca plc (ADR) was upgraded by analysts at Panmure Gordon from a “hold” rating to a “buy” rating.
  • AstraZeneca plc (ADR) was upgraded by analysts at Kepler Capital Markets from a “reduce” rating to a “hold” rating.
  • AstraZeneca plc (ADR) was upgraded by analysts at Credit Suisse from an “underperform” rating to a “neutral” rating.
  • AstraZeneca plc (ADR) had its “hold” rating reaffirmed by analysts at Jefferies Group.
  • AstraZeneca plc (ADR) had its “hold” rating reaffirmed by analysts at Deutsche Bank.

Shares of AstraZeneca plc (NYSE:AZN) opened at 81.09 on Friday. AstraZeneca plc has a one year low of $46.87 and a one year high of $82.68. The stock’s 50-day moving average is $66.6 and its 200-day moving average is $61.17. The company has a market cap of $102.3 billion and a P/E ratio of 48.47.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.